CAR-T cells targeting CD19 have been reported to result in tumor remission of advanced chronic lymphocytic leukemia (CLL) and ALL patients who have failed multiple rounds of chemotherapy (24, 25). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.